Sarcomas are highly metastatic soft tissue and bone cancers and are often difficult to treat. Scientists have had trouble ...
UCLA have created the most extensive collection of patient-derived sarcoma organoids which are miniature versions of a ...
SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced ...
We focus on soft tissue sarcomas, with the exception of gastrointestinal stromal ... collaboration with biologists to identify relevant targets and pathways relevant to tumour growth and, where ...
There are around 100 different subtypes of sarcoma that can be classified into three broad groups: soft tissue sarcoma ... Here, the authors identify a crosstalk mechanism between tumor and ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the ...
The consortium aims to improve outcomes for patients by identifying new drug targets ... We conduct clinical trials and translational studies into numerous types of sarcoma, such as soft tissue ...
Fort Worth, Texas, clinical-stage biopharmaceutical company Actuate said elraglusib has shown a favorable safety profile and antitumor activity across several solid tumors, including melanoma, Ewing ...
They are generally classified into two main types: soft tissue sarcomas, which affect the ... Basic investigations like x ray and MRI can identify the disease which is confirmed with a biopsy.
I am currently developing three dimensional spheroid models for paediatric soft tissue sarcomas. The in vitro models will serve ... improve the prognostication of rhabdomyosarcoma as well as ...
Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate ...